The House of Representatives has filed the FY 2017 Department of Defense (DoD) Appropriations Bill and accompanying explanatory statement. Following is the relevant section pertaining to the Peer-Reviewed Medical Research Program (PRMRP). In addition to increasing PRMRP funding to $300 million for FY 2017 (an increase of $21.3 million), “sleep disorders” is once again included on the eligible conditions list.
This bill will be subject to the emerging discussion over how to finalize all outstanding FY 2017 appropriations measures. The SRS will continue to keep you informed as the process moves forward.
Peer-Reviewed Medical Research Program
The agreement provides $300,000,000 for a peer-reviewed medical research program. The Secretary of Defense, in conjunction with the Service Surgeons General, is directed to select medical research projects of clear scientific merit and direct relevance to military health. Research areas considered under this funding are restricted to the following areas:
acute lung injury, antimicrobial resistance, arthritis, bum pit exposure, chronic migraine and post-traumatic headache, congenital heart disease, constrictive bronchiolitis, diabetes, diarrheal diseases, dystonia, early trauma thermal regulation, eating disorders, emerging infectious diseases, epidermolysis bullosa, focal segmentai glomerulosclerosis, Fragile X, Guillain-Barre syndrome, hepatitis Band C, hereditary angioedema, hydrocephalus, immunomonitoring of intestinal transplants, inflammatory bowel diseases, influenza, integrative medicine, interstitial cystitis, malaria, metals toxicology, mitochondrial disease, musculoskeletal disorders, nanomaterials for bone regeneration, non-opioid pain management, pancreatitis, pathogen-inactivated dried cryoprecipitate, polycystic kidney disease, post-traumatic osteoarthritis, pulmonary fibrosis, respiratory health, Rett syndrome, rheumatoid arthritis, scleroderma, sleep disorders, spinal muscular atrophy, sustained-release drug delivery, tinnitus, tuberculosis, vaccine development for infectious disease, vascular malformations, and women's heart disease. The additional funding provided under the peer-reviewed medical research program shall be devoted only to the purposes listed above.